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Abstract 
Background 
Depression is highly prevalent within individuals diagnosed with schizophrenia, and is 
associated with an increased risk of suicide. There are no current evidence based treatments 
for low mood within this group. The specific targeting of co-morbid conditions within 
complex mental health problems lends itself to the development of short-term structured 
interventions which are relatively easy to disseminate within health services. A brief 
cognitive intervention based on a competitive memory theory of depression, is being 
evaluated in terms of its effectiveness in reducing depression within this group. 
Methods/Design 
This is a single blind, intention-to-treat, multi-site, randomized controlled trial comparing 
Positive Memory Training plus Treatment as Usual with Treatment as Usual alone. 
Participants will be recruited from two NHS Trusts in Southern England. In order to be 
eligible, participants must have a DSM-V diagnosis of schizophrenia or schizo-affective 
disorder and exhibit at least a mild level of depression. Following baseline assessment 
eligible participants will be randomly allocated to either the Positive Memory Training plus 
Treatment as Usual group or the Treatment as Usual group. Outcome will be assessed at the 
end of treatment (3-months) and at 6-month and 9-month post randomization by assessors 
blind to group allocation. The primary outcome will be levels of depression and secondary 
outcomes will be severity of psychotic symptoms and cost-effectiveness. Semi-structured 
interviews will be conducted with all participants who are allocated to the treatment group so 
as to explore the acceptability of the intervention. 
Discussion 
Cognitive behaviour therapy is recommended for individuals diagnosed with schizophrenia. 
However, the number of sessions and length of training required to deliver this intervention 
has caused a limit in availability. The current trial will evaluate a short-term structured 
protocol which targets a co-morbid condition often considered of primary importance by 
service users. If successful the intervention will be an important addition to current initiatives 
aimed at increasing access to psychological therapies for people diagnosed with severe 
mental health problems. 
Trial registration 
Current Controlled Trials. ISRCTN99485756. Registered 13 March 2014. 
Background 
The annual cost of the treatment of schizophrenia within the UK has been estimated at over 
£2billion, which is approximately 3% of the NHS budget [1]. Consequently, the development 
of cost-effective interventions for schizophrenia is a priority. Current UK government 
guidelines recommend psychological therapy for the treatment of schizophrenia. Specifically, 
cognitive-behavioural therapy (CBT), in the form of at least 16 sessions over a minimum of 6 
months, is advised [2]. Most current evidence-based CBT protocols for the treatment of 
schizophrenia are designed to be generic and flexible. This enables the clinician to work with 
the wide range of complex presentations, including high levels of co-morbidity, that are 
associated with a diagnosis of schizophrenia. However, it is often a co-morbid diagnosis such 
as posttraumatic stress disorder or depression that both the clinician and patient consider the 
priority for intervention. 
About half of the people diagnosed with schizophrenia also suffer from depression [3]. This 
co-morbid condition is associated with particularly high levels of health care use, and a 
suicide rate of 5% [4]. The effectiveness of anti-depressants is equivocal [5] in this group. To 
date, there have been no clinical trials to evaluate the effectiveness of a psychological 
intervention which targets the treatment of depression within these co-morbid patients. The 
evidence base that supports psychological interventions for depression, such as CBT [6], 
behavioural activation [7] and mindfulness [8] is derived from trials which have excluded 
individuals diagnosed with schizophrenia. There is some evidence that 6 to 12 months of 
generic CBT targeting the symptoms of schizophrenia does achieve a small to moderate 
effect on mood [9]. However, the training that is required for NHS clinicians to provide this 
generic intervention is lengthy, expensive, and limited to a relatively small number of 
specialists. Consequently, there is limited access to CBT for people diagnosed with 
schizophrenia. The targeting of conditions co-morbid with schizophrenia, such as depression, 
lends itself to the development of short-term structured psychological interventions, which 
can be packaged into the form of a manualised protocol. These interventions are relatively 
easy to disseminate within health services, and can be used by a wide range of clinicians. 
They are also likely to be cost-effective. 
An enhanced therapeutic effect may be obtained through the use of interventions which 
specifically target the cognitive processes associated with mood disorder within this group. A 
recent theoretical account of mood disorder [10] suggests that individuals simultaneously 
hold both positive and negative self-representations. However, depression is associated with 
heightened access to the negative self-representations, with the relevant pathway being 
strengthened through regular activation. Korrelboom and colleagues have developed an 
intervention which consists of a training programme specifically designed to heighten the 
activation of positive self-representations. The intervention, termed competitive memory 
training (CoMeT), has been shown to be effective in reducing levels of depression and 
increasing self-esteem within a range of different disorders [11-15]. Within one study, a 
mediation analysis suggested that the reduction in depression was mediated by self-esteem 
[15]. An adapted form of this intervention termed positive memory training (PoMeT) has 
been developed for use within a U.K. based trial. The PoMeT trial is the first randomised 
controlled trial to specifically target the treatment of depression in people diagnosed with 
schizophrenia. 
Hypotheses 
The primary hypotheses to be tested is whether within patients who are diagnosed with 
schizophrenia and exhibit at least a mild level of depression, those who receive positive 
memory training will demonstrate a higher level of reduction in depressive symptoms than 
those who receive treatment as usual. 
Secondary hypotheses predict that: 
(a) Positive memory training will reduce the level of distressing psychotic symptoms, as 
measured by the Psychotic Symptom Rating Scale [16]. 
(b) Positive memory training will be cost-effective. 
Method 
The trial is funded by the National Institute of Health Research and received ethical approval 
for all sites from the Berkshire Research Ethics Committee (REC ref 13/SC/0634). The RCT 
is conducted by a multidisciplinary team of researchers, clinicians, statisticians and health 
economists within a number of European institutions and NHS Trusts within the South of 
England. 
Design 
A rater-blind randomised controlled trial using intention to treat comparing positive memory 
training (PoMeT) and treatment as usual (TAU) with TAU alone. The intervention is to be 
completed within 3-months from the date of randomisation. Assessments are conducted at 
baseline, 3-months, 6-months and 9-months from randomisation as shown in Figure 1. 
Figure 1 Flow chart of study design. 
The trial is recruiting participants with a diagnosis of schizophrenia or schizoaffective 
disorder with at least a mild level of depression, defined as a score of 14 or over on the Beck 
Depression Inventory II [17]. Recruitment to the trial began in May 2014 and is due to be 
competed in December 2015. Follow-up assessments are due to being in August 2014 and to 
end in September 2016. 
Intervention 
Positive memory training (PoMeT) is designed to enhance access to positive self-
representations resulting in reduced levels of depression and increased self-esteem. It is based 
on a theoretical account of mood disorder which suggests that positive self representations 
are relatively dormant within individuals suffering from depression, at least in part due to 
infrequent activation. The first stage of therapy involves the patient identifying their core 
negative self-representation, such as being “worthless”. Within the first session the therapist 
moves towards the identification of personality characteristics which are inconsistent with 
being “worthless”. Homework involves writing as many specific examples as possible within 
which the patient has demonstrated these characteristics, e.g. being thanked for being a good 
friend. Subsequent sessions move towards working with one of these specific ‘positive 
memories’ in order to maximize the emotional impact. This includes the integrated use of 
imagery, posture and self-statements whilst ‘reliving’ this past positive event. It is important 
that the meaning of the positive event provides a direct challenge to the originally identified 
negative self-representation. A major component of the intervention protocol is daily practise 
of positive self-representation recall in between the weekly sessions. The final stages of the 
intervention involves the patient being trained to activate the positive self-representation at a 
time when an external environmental cue triggers the negative self-representation. 
The intervention is manualised and highly structured. Whilst the original protocol adopted 8 
sessions of one hour, on the advice of a service-user focus group our study protocol allows up 
to 12 sessions of one hour within the 3-month treatment period. 
The treatment requires therapists to have a core mental health profession and a basic 
understanding of cognitive behaviour therapy. Within the current trial the intervention is 
delivered by a nurse who is an accredited cognitive behavioural therapist, a counselling 
psychologist and a clinical psychologist. Supervision is provided by team members with 
relevant expertise both in the intervention and patient group. Adherence to protocol is 
monitored through the use of a measure specifically designed for the current study and aimed 
to differentiate between the delivery of PoMeT and standard CBT or counselling. 
Treatment as usual (TAU) 
Treatment as Usual (TAU) will be provided by the standard in-patient and out-patient 
services provided by the NHS. This will include neuroleptic medication and the possibility of 
other psychosocial interventions. All medication and service input received by both the 
PoMeT + TAU and the TAU groups will be documented during trial assessments. 
Inclusion and exclusion criteria 
Potential participants must meet the inclusion criteria of (i) DSM-V diagnosis of 
schizophrenia of schizoaffective disorder (ii) at least a mild level of depression as measured 
by scoring 14 or more on the Beck Depression Inventory-II [17] (iii) aged between 18 and 65 
(iv) have a sufficient understanding of spoken English to engage with assessments and 
clinical intervention (v) are able and willing to provide informed consent (vi) do no exhibit an 
organic impairment which is considered to be the primary diagnosis and (vii) do not exhibit a 
learning disability. 
Recruitment and randomisation 
Recruitment will take place within two UK NHS Trusts, Berkshire Healthcare Foundation 
Trust and Southern Health Foundation Trust. Eligible participants are identified by trial 
research assistants, working in collaboration with care coordinators based within community 
mental health teams. Potentially eligible participants are invited to take part and provide 
informed consent. Once informed consent has been obtained trained researchers screen 
patient records to confirm eligibility and administer the Beck Depression Inventory in order 
to ascertain whether the patient is experiencing at least a mild level of depressed mood. If the 
patient is eligible the researcher continues with the baseline assessment battery. On 
completion of assessments the participant is randomised to either the PoMeT + TAU or the 
TAU group. 
Randomisation is stratified by site and severity of depression (above and below a BDI-II 
score of 29, i.e. a severe level of depression) using randomised-permuted blocks. Group 
allocation is revealed to the participant, trial manager and trial therapists. 
Measures 
Primary outcome measure 
The primary outcome is current level of depressed mood as assessed by the Beck Depression 
Inventory- II [17]. 
Secondary outcome measures 
Self-esteem is measured using the Roseneberg Self-Esteem Scale [18] which contains ten 
items measured on a four-point scale. The scale measures state self-esteem by asking the 
patient to reflect on their current feelings. 
Psychotic Symptoms are assessed using two measures. The Positive and Negative Syndrome 
Scale (PANSS) [19] includes scales of positive symptoms, negative symptoms and general 
psychopathology and is used widely in schizophrenia research. Also, the Psychotic Symptom 
Rating Scale (PSYRATS) [16] is used to provide detailed information on the clinical 
characteristics of hallucinations and delusions, including distress and impact on functioning. 
Anxiety is measured using the Generalised Anxiety Disorder Assessment (GAD7) [20] which 
includes seven items each describing anxiety symptoms, and endorsed on the basis of 
frequency. Functioning is measured using the Work and Social Adjustment scale [21]. Patient 
well-being is assessed using the Warwick-Edinburgh Mental Well-being Scale [22], a 
fourteen-item questionnaire which includes both hedonic and eudaimonic features which are 
rated on a five-point scale. 
A semi-structured interview will be developed in consultation with service –user focus 
groups to explore the acceptability of the intervention. All participants who are allocated to 
the Positive Memory Training group will be invited to participate in an interview. 
Patients’ health-related quality of life will be measured by the EuroQol EQ-5D [23], a 
generic, multi-attribute utility scale widely used for economic evaluations. In addition, 
patients will complete the ICECAP-A [24] and OxCAP-MH [25] instruments , both based on 
Sen’s capability approach that considers a broad concept of wellbeing including an 
individual’s ability to ‘do’ and ‘be’ the things that are important in life [26]. 
Primary informal carers will complete the EuroQol EQ-5D [23] and the Carer Experience 
Scale [27] via postal questionnaire to measure separately the likely impacts of PoMET on 
carers’ quality of life and wellbeing. 
Costs will be assessed from a broad societal perspective using an amended version of the 
Client Service Receipt Inventory [28] and therapists’ records. These will include information 
on all PoMET treatment related costs, other health care resource use costs (including in-
patient stays, outpatient visits, community mental health service contacts, primary care 
contacts, and medications), social care costs, and broader societal impacts (including costs to 
the patients and their families and lost productivity costs). Costs will be calculated using UK 
national-level unit costs. 
Assessments will be conducted at baseline, 3-months (end of treatment) and at 6-months and 
9-months after randomisation. All measures will be completed at baseline, 3-month and 9-
month assessment. The 6-month assessment includes only measures of depression, patient 
health status (including quality of life and wellbeing) and costs. 
Analysis 
Power 
A sample of 50 per group will have 80% power to detect the PoMeT + TAU group presenting 
with a BDI-II score of 7 or more lower than the TAU group at the 2.5% level of significance 
(two-tailed). 
Planned analysis 
All analyses will be carried out on an intention to treat principle. Outcome measures for the 
intervention and treatment as usual (control) groups will be compared using linear mixed-
effects models. The dependant variables will be the outcome measures at post-intervention 
and follow-up. Outcome measures at baseline, group membership and time will be included 
as fixed explanatory variables. The models will also include random effects for patients to 
allow for the correlation between post-intervention and follow-up outcome measures. 
Additionally, the models will contain interaction between time and group to test whether the 
effects of the intervention and usual treatment vary between post-intervention and follow-up 
time points. Standard diagnostic evaluations of model assumptions will be conducted to 
ensure valid inference. 
The economic evaluation will be a within trial cost-utility analysis comparing the cost-
effectiveness of PoMET in comparison to TAU and will follow the current gold standard 
methods for economic analyses. Cost-effectiveness will be primarily measured in terms of 
cost per quality adjusted life year gained (QALY). Alternative analyses will explore the cost-
effectiveness of PoMET using capability measures. Uncertainty in the base case results will 
be assessed using non-parametric methods and extensive sensitivity analyses [29]. 
Planned subgroup analysis 
Analyses will be conducted so as to assess for the role of self-esteem mediating any observed 
change in levels of depression within the treatment group. Also, self-esteem and depression 
will be assessed as potential mediators of change within the severity of psychotic symptoms 
within the treatment group. 
Discussion 
Although depression is highly prevalent within individuals diagnosed with schizophrenia, 
there are no current evidence based interventions for the treatment of this specific co-morbid 
presentation. Relatively short-term structured interventions are easier to disseminate within 
health services, and therefore the Positive Memory Training protocol being adopted within 
the current trial has the potential to be both widely available and cost-effective. It is also 
envisaged that as the dominant focus of the intervention is on positive past experiences, that 
rates of patient engagement will be high. 
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